Market closed

ACADIA Pharmaceuticals/$ACAD

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Ticker

$ACAD
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
San Diego, United States

Employees

620
Website
www.acadia.com

ACAD Metrics

BasicAdvanced
$3B
23.06
$0.78
0.38
-

$3B

0.38

$29.29

$14.15

3.3M

2.292

1.965

7.003

7.003

8.72%

27.36%

23.057

3.184

5.16

6.31

14.599

47.06%

-185.10%

25.12%

-13.52%

What the Analysts think about ACAD

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.

ACAD Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ACAD Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

ACAD News

AllArticlesVideos
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·4 weeks ago
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Business Wire·1 month ago
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ACAD

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals (ACAD) has a market cap of $3B as of January 15, 2025.

What is the P/E ratio for ACADIA Pharmaceuticals stock?

The price to earnings (P/E) ratio for ACADIA Pharmaceuticals (ACAD) stock is 23.06 as of January 15, 2025.

Does ACADIA Pharmaceuticals stock pay dividends?

No, ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next ACADIA Pharmaceuticals dividend payment date?

ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders.

What is the beta indicator for ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (ACAD) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.